David J Bearss

This inventor holds 50 USPTO granted patents and 31 published patent applications, plus 4 CIPO patents and 16 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: Tolero Pharmaceuticals, Inc., University of Utah Research Foundation, Sumitomo Pharma Oncology, Inc.. Active years: 2006-2025.

USPTO Granted Patents = 50 (Patent Applications = 31)

% Patents Active = 58.0

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 16 (Patent Applications = 34)

Average Co-Inventor Count = 4.1

ph-index = 14

Forward Citations = 594(Granted Patents)

Forward Citations (Not Self Cited) = 444(Dec 10, 2025)

Location History:

Tucson, AZ (US) (2006)
Highland, UT (US) (2008)
Modesto, CA (US) (2006 - 2015)
Cedar Hills, UT (US) (2007 - 2015)
Lehi, UT (US) (2020)
Alpine, UT (US) (2013 - 2023)

Company Filing History:

13 out of 21

Tolero Pharmaceuticals, Inc.

patents

10 out of 1,684

University of Utah Research Foundation

patents

6 out of 11

Sumitomo Pharma Oncology, Inc.

The University of Arizona

patents

6. 3 out of 3

Montigen Pharmaceuticals, Inc.

patents

7. 3 out of 36

Neuropro Technologies, Inc.

patents

8. 3 out of 11

Sumitomo Dainippon Pharma Oncology, Inc.

patents

9. 2 out of 11

Astex Pharmaceuticals, Inc.

patents

10. 1 out of 1

Astex Pharmaceutials, Inc.

patent

11. 1 out of 1

Biolexis Therapeutics, Inc.

patent

12. 2 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

CDK9 Inhibitors

Tyrosine Kinase Inhibitors

Combination Therapies

Alvocidib Prodrugs

JAK Inhibitors

Histone Demethylase Inhibitors

Cancer Treatment

ACVR1 Inhibitors

MCL-1 Inhibitors

Sensitivity Profiling

Bone Growth Compositions

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338261 - Alvocidib prodrugs having increased bioavailability (2025-06-24),

2. 12275738 - CDK9 inhibitors (2025-04-14),

3. 11793802 - Treatment of acute myeloid leukemia (AML) with venetoclax failure (2023-10-24),

4. 11712433 - Compositions comprising PKM2 modulators and methods of treatment using the same (2023-08-01),

5. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),

6. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),

7. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),

8. 11040038 - Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same (2021-06-22),

9. 10835537 - Combination therapies for treatment of cancer (2020-11-17),

10. 10752594 - JAK1 and ALK2 inhibitors and methods for their use (2020-08-25),

11. 10682356 - Combination therapies for treatment of cancer (2020-06-16),

12. 10624880 - Predicting response to alvocidib by mitochondrial profiling (2020-04-21),

13. 10568887 - Combination therapies for treatment of cancer (2020-02-25),

14. 10562925 - Alvocidib prodrugs having increased bioavailability (2020-02-18),

15. 10422788 - Profiling peptides and methods for sensitivity profiling (2019-09-24),

Title: The Innovative Journey of David J Bearss

Introduction:

David J Bearss, a talented inventor hailing from Alpine, UT (US), has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents:

David J Bearss holds several patents in various technological domains, including but not limited to software applications, electronic devices, and communication systems.

Career Highlights:

Throughout his illustrious career, David J Bearss has demonstrated a remarkable ability to transform innovative ideas into tangible inventions. His dedication to pushing the boundaries of technology has led to the development of cutting-edge solutions that have revolutionized the industry.

Collaborations:

David J Bearss has collaborated with leading tech companies, research institutions, and universities to further his research and bring his inventions to life. His collaborative spirit and passion for innovation have been instrumental in his success as an inventor.

Conclusion:

In conclusion, David J Bearss stands as a shining example of creativity and ingenuity in the world of technology. His relentless pursuit of innovation and commitment to excellence continue to inspire aspiring inventors and shape the future of technology.